Remove Bacterium Remove Drugs Remove Genetic Disease Remove Genetics
article thumbnail

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

pharmaphorum

Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data. The post Synlogic preps phenylketonuria drug for phase 3 after mid-stage win appeared first on.

Drugs 98